DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600

Biochemical and Biophysical Research Communications

Volumn 466, Issue 3, 2015, Pages 547-553

  Wu, Ling ^a   Zhang, Jiansheng ^a   Wu, Huiguo ^a   Han, Enkun ^a  

^a Tianjin Baodi Hospital   (China)

Author keywords

Chemo sensitization; Colorectal cancer; DNA PKcs; mTOR; WAY 600

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NU 7026; PROTEIN KINASE INHIBITOR; SINGLE STRANDED DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WAY 600; 2-(MORPHOLIN-4-YL)BENZO(H)CHROMEN-4-ONE; 8-DIBENZOTHIOPHEN-4-YL-2-MORPHOLIN-4-YL-CHROMEN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COLONY FORMATION; COLORECTAL CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; GENE OVEREXPRESSION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; R FACTOR; RNA INTERFERENCE; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; GENE SILENCING; GENETICS; MALE; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; CHROMONES; COLORECTAL NEOPLASMS; DNA-ACTIVATED PROTEIN KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952638987     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.09.068     Document Type: Article

References (32)

1. H.J. Schmoll, and A. Stein Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection Nat. Rev. Clin. Oncol. 11 2014 79 80
2. E.J. Kuipers, T. Rosch, and M. Bretthauer Colorectal cancer screening-optimizing current strategies and new directions Nat. Rev. Clin. Oncol. 10 2013 130 142
3. A. Brouquet, and B. Nordlinger Metastatic colorectal cancer outcome and fatty liver disease Nat. Rev. Gastroenterol. Hepatol. 10 2013 266 267
4. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
5. A.I. Ekstrand, M. Jonsson, A. Lindblom, A. Borg, and M. Nilbert Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer Fam. Cancer 9 2010 125 129
6. Y.J. Zhang, Q. Dai, D.F. Sun, H. Xiong, X.Q. Tian, F.H. Gao, M.H. Xu, G.Q. Chen, Z.G. Han, and J.Y. Fang mTOR signaling pathway is a target for the treatment of colorectal cancer Ann. Surg. Oncol. 16 2009 2617 2628
7. A. Gomez-Pinillos, and A.C. Ferrari mTOR signaling pathway and mTOR inhibitors in cancer therapy Hematol. Oncol. Clin. North Am. 26 2012 483 505 vii
8. K. Yu, L. Toral-Barza, C. Shi, W.G. Zhang, J. Lucas, B. Shor, J. Kim, J. Verheijen, K. Curran, D.J. Malwitz, D.C. Cole, J. Ellingboe, S. Ayral-Kaloustian, T.S. Mansour, J.J. Gibbons, R.T. Abraham, P. Nowak, and A. Zask Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Cancer Res. 69 2009 6232 6240
9. H. Hu, Y. Gu, Y. Qian, B. Hu, C. Zhu, G. Wang, and J. Li DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells Biochem. Biophys. Res. Commun. 452 2014 106 111
10. Y. Tu, C. Ji, B. Yang, Z. Yang, H. Gu, C.C. Lu, R. Wang, Z.L. Su, B. Chen, W.L. Sun, J.P. Xia, Z.G. Bi, and L. He DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survival Mol. Cancer 12 2013 172
11. D. Davidson, L. Amrein, L. Panasci, and R. Aloyz Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond Front. Pharmacol. 4 2013 5
12. S.J. Collis, T.L. DeWeese, P.A. Jeggo, and A.R. Parker The life and death of DNA-PK Oncogene 24 2005 949 961
13. Y. Hosoi, T. Watanabe, K. Nakagawa, Y. Matsumoto, A. Enomoto, A. Morita, H. Nagawa, and N. Suzuki Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer Int. J. Oncol. 25 2004 461 468
14. C. Li, J.F. Cui, M.B. Chen, C.Y. Liu, F. Liu, Q.D. Zhang, J. Zou, and P.H. Lu The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent Cancer Biol. Ther. 16 2015 34 42
15. J.S. Tong, Q.H. Zhang, X. Huang, X.Q. Fu, S.T. Qi, Y.P. Wang, Y. Hou, J. Sheng, and Q.Y. Sun Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells PLoS One 6 2011 e16781
16. J. Feng, J. Park, P. Cron, D. Hess, and B.A. Hemmings Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase J. Biol. Chem. 279 2004 41189 41196
17. Y. Zhang, J. Zhou, X. Cao, Q. Zhang, C.U. Lim, R.L. Ullrich, S.M. Bailey, and H.L. Liber Partial deficiency of DNA-PKcs increases ionizing radiation-induced mutagenesis and telomere instability in human cells Cancer Lett. 250 2007 63 73
18. T. Kon, X. Zhang, Q. Huang, Z. Yang, S. Liu, B. Yan, F. Li, H. Wang, and C.Y. Li Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA Transl. Cancer Res. 1 2012 4 14
19. S. Vidal-Eychenie, C. Decaillet, J. Basbous, and A. Constantinou DNA structure-specific priming of ATR activation by DNA-PKcs J. Cell Biol. 202 2013 421 429
20. D.W. Chan, B.P. Chen, S. Prithivirajsingh, A. Kurimasa, M.D. Story, J. Qin, and D.J. Chen Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks Genes Dev. 16 2002 2333 2338
21. A. Tichy, E. Novotna, K. Durisova, B. Salovska, R. Sedlarikova, J. Pejchal, L. Zarybnicka, J. Vavrova, Z. Sinkorova, and M. Rezacova Radio-sensitization of human leukaemic molt-4 cells by DNA-dependent protein kinase inhibitor, NU7026 Acta Medica (Hradec Kralove) 55 2012 66 73
22. Y. Zhao, H.D. Thomas, M.A. Batey, I.G. Cowell, C.J. Richardson, R.J. Griffin, A.H. Calvert, D.R. Newell, G.C. Smith, and N.J. Curtin Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Cancer Res. 66 2006 5354 5362
23. T. Wechsler, B.P. Chen, R. Harper, K. Morotomi-Yano, B.C. Huang, K. Meek, J.E. Cleaver, D.J. Chen, and M. Wabl DNA-PKcs function regulated specifically by protein phosphatase 5 Proc. Natl. Acad. Sci. U. S. A. 101 2004 1247 1252
24. J.B. Easton, and P.J. Houghton mTOR and cancer therapy Oncogene 25 2006 6436 6446
25. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
26. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat. Rev. Cancer 6 2006 729 734
27. Q. Liu, C. Thoreen, J. Wang, D. Sabatini, and N.S. Gray mTOR Mediated Anti-Cancer Drug Discovery Drug Discov. Today Ther. Strateg. 6 2009 47 55
28. D.A. Altomare, and J.R. Testa Perturbations of the AKT signaling pathway in human cancer Oncogene 24 2005 7455 7464
29. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
30. A.M. Dragoi, X. Fu, S. Ivanov, P. Zhang, L. Sheng, D. Wu, G.C. Li, and W.M. Chu DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA EMBO J. 24 2005 779 789
31. L. Deriano, O. Guipaud, H. Merle-Beral, J.L. Binet, M. Ricoul, G. Potocki-Veronese, V. Favaudon, Z. Maciorowski, C. Muller, B. Salles, L. Sabatier, and J. Delic Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway Blood 105 2005 4776 4783
32. Y. Nishida, N. Mizutani, M. Inoue, Y. Omori, K. Tamiya-Koizumi, A. Takagi, T. Kojima, M. Suzuki, Y. Nozawa, Y. Minami, K. Ohnishi, T. Naoe, and T. Murate Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines Biochim. Biophys. Acta 1839 2014 265 274